TILsOV
Phase NA Terminated
36 enrolled
ACCRAPAN
Phase 2 Terminated
21 enrolled
GEMCOL
Phase 2 Terminated
19 enrolled
ANOXICOL
Phase NA Terminated
9 enrolled
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Phase 3 Terminated
358 enrolled
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Phase 1/2 Terminated
5 enrolled
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
Phase 1 Terminated
4 enrolled
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Phase 1 Terminated
17 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
FAB
Phase 2 Terminated
27 enrolled
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Phase 1/2 Terminated
40 enrolled
A Study of PHN-010 in Patients With Advanced Solid Tumors
Phase 1 Terminated
26 enrolled
HPV16 E6 TCR T Cells for Cervical Carcinoma
Phase 1/2 Terminated
5 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Phase 2 Terminated
7 enrolled 10 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Phase 2 Terminated
71 enrolled
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Phase 2 Terminated
19 enrolled
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase 1 Terminated
18 enrolled 19 charts
Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer
Phase NA Terminated
137 enrolled 15 charts
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
Terminated
22 enrolled
BASICS
Phase NA Terminated
3 enrolled
ENDOCOL
Phase NA Terminated
3 enrolled
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1 Terminated
50 enrolled
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Phase 2 Terminated
36 enrolled 11 charts
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Phase 2 Terminated
166 enrolled 43 charts
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
ARTIST
Phase 2 Terminated
36 enrolled
PAVO
Phase 2 Terminated
22 enrolled 17 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Phase 1 Terminated
25 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors
Phase NA Terminated
22 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Phase 1 Terminated
3 enrolled
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Phase 2 Terminated
4 enrolled 8 charts
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Phase 2/3 Terminated
600 enrolled
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Phase 1 Terminated
58 enrolled
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Phase 2 Terminated
210 enrolled
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
Phase 2 Terminated
9 enrolled 8 charts
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
PAIR HPV
Phase NA Terminated
26 enrolled
COCHISE
Phase 2 Terminated
18 enrolled 9 charts